J. W. Louwerenburg

A Randomized Controlled Trial in Second-Generation Zotarolimus-Eluting Resolute Stents Versus Everolimus-Eluting Xience V Stents in Real-World Patients

Clemens von Birgelen, Mounir W.Z. Basalus, Kenneth Tandjung et al. · Journal of the American College of Cardiology · 2012 · 248 citations · Full text

Medicine, Cardiology, Pharmacotherapy +17

Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial

Clemens von Birgelen, Marlies M. Kok, Liefke C. van der Heijden et al. · The Lancet · 2016 · 248 citations · Full text

Medicine, Cardiology, Pharmacotherapy +13

Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial

Clemens von Birgelen, Hanim Sen, Ming Kai Lam et al. · The Lancet · 2013 · 198 citations

Medicine, Cardiology, Internal Medicine +15

Clinical Outcome Following Stringent Discontinuation of Dual Antiplatelet Therapy After 12 Months in Real-World Patients Treated With Second-Generation Zotarolimus-Eluting Resolute and Everolimus-Eluting Xience V Stents

Kenneth Tandjung, Hanim Sen, Ming Kai Lam et al. · Journal of the American College of Cardiology · 2013 · 71 citations · Full text

Medicine, Cardiology, Pharmacotherapy +13

5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents

Paolo Zocca, Marlies M. Kok, Kenneth Tandjung et al. · JACC: Cardiovascular Interventions · 2018 · 53 citations · Full text

Medicine, Cardiology, Cardiovascular Pharmacotherapy +12